Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Pate, Girishchandra B ^a   Zhou, Hongyan ^a   Ponce, Amalia ^a   Harris, Greg ^a   Chen, Wangxue ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARCHAEAL LIPID MUCOSAL VACCINE ADJUVANT; BACTERIUM ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 17; TULAREMIA VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; CHEMOKINE; CYTOKINE; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CELL FREE SYSTEM; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG DELIVERY SYSTEM; FEMALE; FRANCISELLA TULARENSIS; INFECTION PREVENTION; LUNG LAVAGE; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; SPLEEN CELL; SURVIVAL RATE; TREATMENT OUTCOME; TULAREMIA; ANIMAL; HUMAN; IMMUNIZATION; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MICROBIOLOGY; MUCOSA; RESPIRATORY TRACT DISEASE; TISSUE DISTRIBUTION;

ARCHAEA; BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; MUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; CELL-FREE SYSTEM; CHEMOKINES; CYTOKINES; FRANCISELLA TULARENSIS; HUMANS; IMMUNIZATION; INFLAMMATION; INTERLEUKIN-17; MICE; MUCOUS MEMBRANE; OVALBUMIN; RESPIRATORY TRACT DISEASES; TISSUE DISTRIBUTION;

EID: 78650827255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015574     Document Type: Article

References (32)

1. Jakobsen H, Jonsdottir I (2003) Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines? Scand J Immunol 58: 119-128.
2. Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, et al. (1997) Current opinions for vaccine delivery systems by mucosal routes. J Control Release 48: 243-257.
3. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
4. Singh M, O'Hagan DT (2002) Recent advances in vaccine adjuvants. Pharm Res 19: 715-728.
5. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484.
6. Giudice EL, Campbell JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev 58: 68-89.
7. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5: 905-916.
8. Holmgren J, Czerkinsky C, Eriksson K, Harandi AM (2003) Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 Suppl 2: S89-95.
9. Lemoine D, Francotte M, Preat V (1998) Nasal vaccines. From fundamental concepts to vaccine development. S T P Pharma Sci 8: 5-18.
10. Ryan EJ, Daly LM, Mills KHG (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19: 293-304.
11. Ogra PL, Faden H, Welliver RC (2001) Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14: 430-445.
12. Kemble G, Greenberg H (2003) Novel generations of influenza vaccines. Vaccine 21: 1789-1795.
13. Patel GB, Zhou H, Ponce A, Chen W (2007) Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 25: 8622-8636.
14. Patel GB, Ponce A, Zhou H, Chen W (2008) Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int J Toxicol 27: 329-339.
15. Choquet CG, Patel GB, Beveridge TJ, Sprott GD (1994) Stability of pressureextruded liposomes made from archaeobacterial ether lipids. Appl Microbiol Biotechnol 42: 375-384.
16. Sprott GD, Patel GB, Krishnan L (2003) Archaeobacterial ether lipid liposomes as vaccine adjuvants. Methods Enzymol 373: 155-172.
17. Patel GB, Ponce A, Zhou H, Chen W (2008) Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J Liposome Res 18: 127-143.
18. KuoLee R, Harris G, Conlan JW, Chen W (2007) Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25: 3781-3791.
19. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, et al. (2007) Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 75: 5597-5608.
20. Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, et al. (2009) Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol 182: 4899-4909.
21. Baron SD, Singh R, Metzger DW (2007) Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 75: 2152-2162.
22. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, et al. (2009) Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol 16: 444-452.
23. KuoLee R, Chen W (2007) Vaccines and therapeutic agents for tularemia. Expert Opin on Ther Pat 17: 267-275.
24. Stenmark S, Lindgren H, Tarnvik A, Sjostedt A (2003) Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 35: 73-80.
25. Stenmark S, Sjostedt A (2004) Transfer of specific antibodies results in increased expression of TNF-alpha and IL12 and recruitment of neutrophils to the site of a cutaneous Francisella tularensis infection. J Med Microbiol 53: 501-504.
26. Rhinehart-Jones TR, Fortier AH, Elkins KL (1994) Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 62: 3129-3137.
27. Unkeless JC, Scigliano E, Freedman VH (1988) Structure and Function of Human and Murine Receptors for IgG. Annu Rev Immunol 6: 251-281.
28. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
29. Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, et al. (2010) The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One 5: e11176.
30. Woolard MD, Hensley LL, Kawula TH, Frelinger JA (2008) Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun 76: 2651-2659.
31. Sjostedt A, North RJ, Conlan JW (1996) The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142: 1369-1374.
32. Conlan JW, KuoLee R, Shen H, Webb A (2002) Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog 32: 127-134.